David W Kimberlin, Inmaculada Aban, Kalyani Peri, Javier K Nishikawa, Jolanta Bernatoniene, Marieke Emonts, Nigel Klein, Alasdair Bamford, Roberta L DeBiasi, Saul N Faust, Christine E Jones, Paddy McMaster, Mary Caserta, Amina Ahmed, Mike Sharland, Gail Demmler-Harrison, Scott Hackett, Pablo J Sánchez, Fiona Shackley, Dominic Kelly, Penelope H Dennehy, Gregory A Storch, Richard J Whitley, Paul Griffiths
OBJECTIVE: The objective of this study was to determine if valganciclovir initiated after 1 month of age improves congenital cytomegalovirus-associated sensorineural hearing loss. STUDY DESIGN: We conducted a randomized, double-blind, placebo-controlled phase 2 trial of 6 weeks of oral valganciclovir at US (n = 12) and UK (n = 9) sites. Patients of ages 1 month through 3 years with baseline sensorineural hearing loss were enrolled...
February 2, 2024: Journal of Pediatrics